|Poll|November 11, 2014

Mini-quiz: Strategies for Switching Antipsychotics

When acute, severe adverse effects from a pre-switch antipsychotic occurs, what strategy is recommended? Take the quiz and learn more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

June 5th 2026

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

ByLeah Kuntz

June 4th 2026

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

ByLeslie L. Citrome, MD, MPH

June 3rd 2026

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

ByKim Do, PhD,Jessica Walters

June 3rd 2026

FDA Issues CRL for CTx-1301 for Treatment of ADHD

ByJessica Walters

June 2nd 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini-quiz: Strategies for Switching Antipsychotics

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Suicide Risk Assessment in Patients Denying Suicidal Intent

New Name, New Path for Psychiatry: The Future of the DSM